Table 2 Demographics and clinical characteristics of the participants at the baseline

Sex/male (%)

28 (62.22%)

24 (60.00%)

29 (58.00%)

31 (59.62%)

0.981

Age (year)

69.13 ± 3.62

69.23 ± 5.78

69.40 ± 4.25

69.00 ± 5.25

0.979

BMI

26.68 ± 2.67

26.23 ± 2.04

26.02 ± 2.69

27.00 ± 2.09

0.174

Glycemic control

0.448

Metformin with alogliptin

18 (40.00%)

14 (35.00%)

24 (48.00%)

/

Metformin with glimepiride

27 (60.00%)

26 (65.00%)

26 (52.00%)

/

SARS-CoV-2 vaccinators

32 (71.11%)

29 (72.50%)

37 (74.00%)

40 (76.92%)

0.926

T-score of BMD

0.20 ± 0.72^*#

-2.81 ± 0.22

-2.77 ± 0.20

0.31 ± 0.51^*#

PPD (mm)

1.90 ± 0.29^*

4.55 ± 0.22

1.89 ± 0.34^*

1.81 ± 0.26^*

CAL (mm)

0.55 ± 0.30^*

5.58 ± 0.21

0.57 ± 0.29^*

0.46 ± 0.35^*

BI

1.81 ± 0.24^*

3.64 ± 0.45

1.79 ± 0.29^*

1.73 ± 0.20^*

PLI

0.40 ± 0.23^*

2.26 ± 0.33

0.38 ± 0.20^*

0.32 ± 0.20^*